Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration

被引:1
|
作者
Vujosevic, Stela [1 ,2 ]
Lupidi, Marco [3 ]
Donati, Simone [4 ]
Astarita, Carlo [5 ]
Gallinaro, Valentina [5 ]
Pilotto, Elisabetta [6 ]
机构
[1] Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy
[2] IRCCS MultiMed, Eye Clin, Milan, Italy
[3] Polytech Univ Marche, Dept Expt & Clin Med, Eye Clin, Ancona, Italy
[4] Univ Insubria Varese, Dept Med & Surg, Varese, Italy
[5] AbbVie Srl, SR 148 Pontina, I-04011 Campoverde, LT, Italy
[6] Univ Padua, Dept Neurosci Ophthalmol, Padua, Italy
关键词
Diabetic Macular Edema; Neovascular age-related macular degeneration; Inflammation; Intravitreal corticosteroid implant; VEGF inhibitors; ENDOTHELIAL GROWTH-FACTOR; GLYCATION END-PRODUCTS; PROTEIN-KINASE-C; EARLY CHOROIDAL NEOVASCULARIZATION; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL-CELLS; AQUEOUS-HUMOR; OXIDATIVE STRESS; INTRAVITREAL AFLIBERCEPT; CYTOKINE CONCENTRATION;
D O I
10.1016/j.survophthal.2024.07.006
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are multifactorial disorders that affect the macula and cause significant vision loss. Although inflammation and neoangiogenesis are hallmarks of DME and nAMD, respectively, they share some biochemical mediators. While inflammation is a trigger for the processes that lead to the development of DME, in nAMD inflammation seems to be the consequence of retinal pigment epithelium and Bruch membrane alterations. These pathophysiologic differences may be the key issue that justifies the difference in treatment strategies. Vascular endothelial growth factor inhibitors have changed the treatment of both diseases, however, many patients with DME fail to achieve the established therapeutic goals. From a clinical perspective, targeting inflammatory pathways with intravitreal corticosteroids has been proven to be effective in patients with DME. On the contrary, the clinical relevance of addressing inflammation in patients with nAMD has not been proven yet. We explore the role and implication of inflammation in the development of nAMD and DME and its therapeutical relevance.
引用
收藏
页码:870 / 881
页数:12
相关论文
共 50 条
  • [31] Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes
    Agostini, Hansjuergen
    Abreu, Francis
    Baumal, Caroline R.
    Chang, Dolly S.
    Csaky, Karl G.
    Demetriades, Anna M.
    Kodjikian, Laurent
    Lim, Jennifer I.
    Margaron, Philippe
    Mones, Jordi M.
    Peto, Tunde
    Ricci, Federico
    Rueth, Matthias
    Singh, Rishi P.
    Stoilov, Ivaylo
    Swaminathan, Balakumar
    Willis, Jeffrey R.
    Westenskow, Peter D.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2024, 262 (11) : 3437 - 3451
  • [32] Macular atrophy development in neovascular age-related macular degeneration
    Calugaru, Dan
    Calugaru, Mihai
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (01) : NP307 - NP308
  • [33] Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration
    Ting, TD
    Oh, M
    Cox, TA
    Meyer, CH
    Toth, CA
    ARCHIVES OF OPHTHALMOLOGY, 2002, 120 (06) : 731 - 737
  • [34] Role of vitreous in the pathogenesis of neovascular age-related macular degeneration
    Boneva, Stefaniya
    Haritoglou, Christos
    Schultheiss, Maximilian
    Binder, Susanne
    Sebagy, J.
    OPHTHALMOLOGIE, 2023, 120 (10): : 992 - 998
  • [35] Role of interleukin 33 in neovascular age-related macular degeneration
    Theodoropoulou, Sofia
    Doyle, Sarah
    Copland, David
    Liu, Jian
    Wu, Jiahui
    Campbell, Matthew
    Dick, Andrew D.
    LANCET, 2016, 387 : 99 - 99
  • [36] Role of inflammasome activation in neovascular age-related macular degeneration
    Marneros, Alexander G.
    FEBS JOURNAL, 2023, 290 (01) : 28 - 36
  • [37] Ranibizumab for neovascular age-related macular degeneration
    Rosenfeld, Philip J.
    Brown, David M.
    Heier, Jeffrey S.
    Boyer, David S.
    Kaiser, Peter K.
    Chung, Carol Y.
    Kim, Robert Y.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14): : 1419 - 1431
  • [38] Pegaptanib for neovascular age-related macular degeneration
    Gragoudas, ES
    Adamis, AP
    Cunningham, ET
    Feinsod, M
    Guyer, DR
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27): : 2805 - 2816
  • [39] Management of neovascular age-related macular degeneration
    Schmidt-Erfurth, Ursula M.
    Pruente, Christian
    PROGRESS IN RETINAL AND EYE RESEARCH, 2007, 26 (04) : 437 - 451
  • [40] Imaging in Neovascular Age-Related Macular Degeneration
    Gess, Adam J.
    Fung, Anne E.
    Rodriguez, Jorge G.
    SEMINARS IN OPHTHALMOLOGY, 2011, 26 (03) : 225 - 233